MDGL
Madrigal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$541.08
−0.28%Aug 22, 2026, 07:07 UTC
Allworth Financial LP acquired a new position in Madrigal Pharmaceuticals, Inc. by purchasing 3,562 shares valued at approximately $1,913,000 in the second quarter, as disclosed in a recent SEC filing.
Source:Aug 15, 2026, 09:02 UTC
Madrigal Pharmaceuticals expanded its development pipeline around the MASH therapy Rezdiffra, preparing for several potential clinical catalysts.
Source:Aug 12, 2026, 12:13 UTC
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., to its Board of Directors on August 12, 2026.
Source:Jul 30, 2026, 00:00 UTC
Madrigal Pharmaceuticals reported Q2 2026 financial results, with Rezdiffra net sales of $364.3 million and a net loss of $57.9 million.
Jul 13, 2026, 12:00 UTC
Madrigal Pharmaceuticals received three new resmetirom patents from the USPTO, including two for Rezdiffra in F2/F3 and one for treating well-compensated cirrhosis (F4c).
Source:Jul 2, 2026, 01:19 UTC
Ribo and Madrigal achieved the first candidate drug nomination milestone in their siRNA partnership for MASH therapies.
Source:Jun 1, 2026, 23:59 UTC
David Soergel, Chief Medical Officer of Madrigal Pharmaceuticals, sold 1,042 shares of the company's common stock on June 1, 2026, for a total of $516,561.
Source: